{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Dermatologic Therapy",
      "autoimmune bullous disease"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32621628",
  "DateCompleted": {
    "Year": "2021",
    "Month": "01",
    "Day": "13"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "07",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "07",
        "Day": "25"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e13956",
      "10.1111/dth.13956"
    ],
    "Journal": {
      "ISSN": "1529-8019",
      "JournalIssue": {
        "Volume": "33",
        "Issue": "6",
        "PubDate": {
          "Year": "2020",
          "Month": "Nov"
        }
      },
      "Title": "Dermatologic therapy",
      "ISOAbbreviation": "Dermatol Ther"
    },
    "ArticleTitle": "Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era.",
    "Pagination": {
      "StartPage": "e13956",
      "MedlinePgn": "e13956"
    },
    "Abstract": {
      "AbstractText": [
        "Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID-19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID-19, are evolving and updated every day."
      ],
      "CopyrightInformation": "\u00a9 2020 Wiley Periodicals LLC."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-8213-6056"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran."
          }
        ],
        "LastName": "Azimi",
        "ForeName": "Seyyede Zeinab",
        "Initials": "SZ"
      },
      {
        "Identifier": [
          "0000-0001-7274-4840"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran."
          }
        ],
        "LastName": "Firooz",
        "ForeName": "Alireza",
        "Initials": "A"
      },
      {
        "Identifier": [
          "0000-0003-2971-0199"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Dermatology, University of New South Wales, Sydney, New South Wales, Australia."
          }
        ],
        "LastName": "Murrell",
        "ForeName": "Dedee F",
        "Initials": "DF"
      },
      {
        "Identifier": [
          "0000-0003-1020-8895"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran."
          }
        ],
        "LastName": "Daneshpazhooh",
        "ForeName": "Maryam",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Dermatol Ther",
    "NlmUniqueID": "9700070",
    "ISSNLinking": "1396-0296"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunosuppressive Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Autoimmunity"
    },
    {
      "QualifierName": [
        "epidemiology",
        "immunology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunocompromised Host"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Immunosuppressive Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "immunology"
      ],
      "DescriptorName": "Pemphigoid, Bullous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Assessment"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ],
  "CoiStatement": "The authors declare no conflicts of interest."
}